SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Increase in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 52,600 shares, a growth of 22.3% from the March 15th total of 43,000 shares. Based on an average daily trading volume, of 54,500 shares, the short-interest ratio is currently 1.0 days. Approximately 0.1% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SOPH. BTIG Research lifted their price target on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research report on Wednesday, March 6th.

SOPHiA GENETICS Price Performance

SOPH opened at $5.00 on Monday. The company has a 50-day moving average of $4.84 and a 200-day moving average of $4.31. SOPHiA GENETICS has a 1-year low of $2.13 and a 1-year high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.12). SOPHiA GENETICS had a negative net margin of 126.63% and a negative return on equity of 47.40%. The business had revenue of $17.05 million for the quarter, compared to the consensus estimate of $16.78 million. During the same period in the prior year, the company earned ($0.22) EPS. On average, sell-side analysts anticipate that SOPHiA GENETICS will post -1.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of SOPHiA GENETICS during the second quarter valued at approximately $31,000. Jane Street Group LLC acquired a new position in shares of SOPHiA GENETICS during the first quarter valued at approximately $80,000. Renaissance Technologies LLC acquired a new position in shares of SOPHiA GENETICS during the second quarter valued at approximately $63,000. Two Sigma Securities LLC acquired a new position in shares of SOPHiA GENETICS during the first quarter valued at approximately $90,000. Finally, JPMorgan Chase & Co. increased its stake in shares of SOPHiA GENETICS by 3,090.2% during the fourth quarter. JPMorgan Chase & Co. now owns 31,392 shares of the company’s stock valued at $65,000 after acquiring an additional 30,408 shares during the period. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.